

1 **Title: A gene expression map of host immune response in human brucellosis**

2

3 **Authors:** Ioannis Mitroulis<sup>1,2</sup>, Akrivi Chrysanthopoulou<sup>1</sup>, Georgios Divolis<sup>3</sup>,  
4 Charalampos Ioannidis<sup>4</sup>, Maria Ntinopoulou<sup>1</sup>, Athanasios Tasis<sup>1</sup>, Theocharis  
5 Konstantinidis<sup>1,5</sup>, Natalia Soteriou<sup>6</sup>, George Lallas<sup>6</sup>, Stella Mitka<sup>7</sup>, Mathias Lesche<sup>8</sup>,  
6 Andreas Dahl<sup>8</sup>, Stephanie Gembardt<sup>4</sup>, Maria Panopoulou<sup>5</sup>, Paschalis Sideras<sup>3</sup>, Ben  
7 Wielockx<sup>4</sup>, Ünal Coskun<sup>4</sup>, Konstantinos Ritis<sup>1,2</sup>, Panagiotis Skendros<sup>1,2\*</sup>

8

9 **Affiliations:** <sup>1</sup>Laboratory of Molecular Hematology, Democritus University of  
10 Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece, <sup>2</sup>First  
11 Department of Internal Medicine, Democritus University of Thrace, University  
12 Hospital of Alexandroupolis, Alexandroupolis, Greece; <sup>3</sup>Biomedical Research  
13 Foundation Academy of Athens, Center for Clinical, Experimental Surgery and  
14 Translational Research, Athens, Greece; <sup>4</sup>Institute for Clinical Chemistry and  
15 Laboratory Medicine, Faculty of Medicine, Technische Universität Dresden, 01307  
16 Dresden, Germany; <sup>5</sup>Laboratory of Microbiology, Democritus University of Thrace,  
17 University Hospital of Alexandroupolis, Alexandroupolis, Greece; <sup>6</sup>P. Zafiropoulos  
18 SA, Athens, Greece; <sup>7</sup>School of Biomedical Sciences, International Hellenic  
19 University, Thessaloniki, Greece; <sup>8</sup>DRESDEN-concept Genome Center, c/o Center  
20 for Molecular and Cellular Bioengineering, Technische Universität Dresden, Dresden,  
21 Germany

22

23 **\*Correspondence:**

24 Panagiotis Skendros, MD, PhD, University Hospital of Alexandroupolis, Dragana,  
25 Alexandroupolis 68100, Greece. E-mail: [pskendro@med.duth.gr](mailto:pskendro@med.duth.gr)

26 **ABSTRACT**

27 Brucellosis is a common zoonotic disease caused by intracellular pathogens of the  
28 genus *Brucella*. *Brucella* infects macrophages and evades clearance mechanisms,  
29 which results in chronic parasitism. Herein, we studied the molecular changes that  
30 take place in human brucellosis both *in vitro* and *in vivo*. RNA sequencing was  
31 performed in primary human macrophages (M $\phi$ ) and polymorphonuclear neutrophils  
32 (PMNs) infected with clinical strains of *B. melitensis*. We observed a downregulation  
33 in the expression of genes involved in host response, such as TNF signaling, IL-1 $\beta$   
34 production and phagosome formation in M $\phi$ , and phosphatidylinositol signaling and  
35 TNF signaling in PMNs, being in line with the ability of the pathogen to survive  
36 within phagocytes. Further transcriptomic analysis of isolated peripheral blood  
37 mononuclear cells (PBMCs) and PMNs from patients with acute brucellosis before  
38 treatment initiation and after successful treatment revealed a positive correlation of  
39 the molecular signature of active disease with pathways associated with response to  
40 interferons (IFN). We identified 24 common genes that were significantly altered in  
41 both PMNs and PBMCs, including genes involved in IFN signaling that were  
42 downregulated after treatment in both cell populations, and *IL1R1* that was  
43 upregulated. The levels of several inflammatory mediators were evaluated in the  
44 serum of these patients, and we observed increased levels of IFN- $\gamma$ , IL-1 $\beta$  and IL-6  
45 before the treatment of acute brucellosis. An independent cohort of patients with  
46 chronic brucellosis also revealed the increased levels of IFN- $\gamma$  during relapse  
47 compared to remissions. Taken together, this study provides for the first time an in-  
48 depth analysis of the molecular alterations that take place in human phagocytes upon  
49 infection, and in peripheral blood immune populations during active disease.

50 **Keywords**

51 Brucellosis; immunity; transcriptomics; macrophages; polymorphonuclear

52 neutrophils; peripheral blood mononuclear cells

## 53 INTRODUCTION

54 Brucellosis is a common bacterial zoonotic disease worldwide and an emerging  
55 zoonosis in several developed countries (1,2). Despite its importance in public health  
56 remains widespread and neglected in many areas, including southeastern Europe,  
57 Asia, Central and Latin America, and Africa (2,3). It is caused by intracellular  
58 pathogens of the genus *Brucella* that have domestic animals, mainly goats, sheep and  
59 cows, as natural reservoirs. The disease is transmitted to humans by consumption of  
60 unpasteurized milk and dairy products or by occupational contact with infected  
61 animals (4). Additionally, *Brucella* is highly infectious through the aerosol route, thus  
62 is considered as one of the most common laboratory-acquired pathogens and is also  
63 classified as a category B agent on the biodefense list (5,6).

64 Human brucellosis causes high morbidity and protean clinical manifestations,  
65 mimicking many infectious and non-infectious diseases since it can affect multiple  
66 organs. Despite early diagnosis and prolonged therapy with antibiotics is associated  
67 with substantial residual disability (4,7). Up to 30% of patients develop chronic  
68 disease, which is characterized by atypical clinical manifestations, high frequency of  
69 focal complications such as spondylitis, chronic fatigue syndrome, and relapses (7,8).

70 Host protection against *Brucella* and prevention of its intracellular parasitism in  
71 macrophages depends on cell-mediated immunity, involving adequate Th1 immune  
72 response, with significant production of interferon gamma (IFN- $\gamma$ ) (8). Recent data  
73 support also an emerging key role of innate immunity and neutrophils in early  
74 proinflammatory responses against *Brucella* that may affect T-cell dynamics during  
75 infection (9,10). On the other hand, *Brucella* has developed various stealthy strategies  
76 to evade innate and adaptive immune responses, in order to establish intracellular  
77 long-term survival and replication (9,11). Several studies have demonstrated that

78 patients with chronic brucellosis display defective cell-mediated immunity  
79 (brucellosis-acquired cellular anergy) probably due to modulation of host cellular  
80 immunity by *Brucella* (12). However, immunopathogenesis of human brucellosis  
81 remains incompletely understood and integrated molecular data that characterize  
82 complex interactions between *Brucella* and host immunity are missing today.  
83 Here, we provide a gene expression map that guides the molecular signature of  
84 macrophages (M $\phi$ ) and polymorphonuclear neutrophils (PMNs) during the crucial  
85 early events of *Brucella* infection. Moreover, we analyse the transcriptomic alterations  
86 that take place concomitantly in peripheral blood mononuclear cells (PBMCs) and  
87 PMNs of patients upon treatment uncovering candidate molecular targets and  
88 pathways that may characterize active infection and disease eradication.

## 89 **MATERIALS AND METHODS**

### 90 **Patients**

91 Ten adult patients with acute brucellosis were recruited. EDTA anticoagulated blood  
92 and serum were collected from patients with active brucellosis before the initiation of  
93 antibiotic treatment and three months after the completion of treatment, when all  
94 patients were successfully treated. The diagnosis was based on compatible clinical  
95 manifestations in combination with high serum titers of anti-brucellar antibodies  
96 (Wright's agglutination test  $\geq 160$ ) or a four-fold increase of the initial titers in two-  
97 paired samples drawn 2 weeks apart, or/and Brucella isolation. None of these patients  
98 suffered any relapse during a six-month post-treatment follow-up period. Patient  
99 characteristics and treatment are described in Table 1. PBMCs and PMNs were  
100 simultaneously isolated. RNA was isolated using TRIzol reagent (ThermoScientific).  
101 Sera from a second cohort of 25 chronic relapsing brucellosis patients at clinical  
102 relapse and remission, were also used. These patients had a disease duration of  $\geq 12$   
103 months in combination with positive serum agglutination tests (SATs) or/and  
104 complement fixation test, or/and Brucella isolation (Supplementary Table 1).  
105 Exclusion criteria were co-existence of other infectious, neoplastic or autoimmune  
106 disease, administration of immunomodulating agents or vaccination for at least 4  
107 weeks before the entry to study, and pregnancy. The study was approved by the Local  
108 Scientific and Ethics Committee of the University Hospital of Alexandroupolis,  
109 Greece. All subjects provided written informed consent in accordance with the  
110 principles expressed in the Declaration of Helsinki.

### 111 **M $\phi$ differentiation**

112 Human M $\phi$  were differentiated from isolated PBMCs from four control subjects, as  
113 previously described with modifications (13). In brief, PBMCs were isolated from

114 healthy donors by density gradient centrifugation, using Histopaque 1077 (Sigma). To  
115 promote M $\phi$  differentiation, monocytes were isolated using plastic adherence and  
116 cells were cultured in the presence of 10% autologous serum for 6 days.

### 117 ***In vitro* infection**

118 Clinical strains of *B. melitensis* were used for *in vitro* experiments. Bacterial inoculum  
119 for cell infection was cultured on blood agar for 3 days. Bacterial suspension with 0.5  
120 McFarland was opsonized for 30 minutes using human serum and then diluted in  
121 RPMI and  $\sim 10^7$  bacteria in 0.5 ml of RPMI were added to each well (20 MOI) of  
122 PMNs or M $\phi$ . Subsequently, cells were cultured for 0.5h for PMNs and 2h and 24h  
123 for M $\phi$ , washed twice and RNA was isolated, using TRIzol reagent  
124 (ThermoScientific). Untreated PMNs and untreated M $\phi$ , cultured for 2h served as  
125 control, respectively. The experimental procedure with *B. melitensis* was performed at  
126 biosafety level 3.

### 127 **RNA sequencing**

128 RNA sequencing for M $\phi$  and PBMCs was performed as previously described (14). To  
129 analyze RNA sequencing data, fragments were aligned with GSNAP (2020-12-16) to  
130 the human reference (hg38), and Ensembl annotation version 98 was used for the  
131 splice site support. Uniquely aligned fragments were counted with featureCounts  
132 (subread v2.0.1), again with the support of the Ensembl annotation. The exploratory  
133 analysis was performed with the DESeq 2 (v1.24.0) package within R (v3.6.3). Bias  
134 for patients was assessed using an exploratory correction with the variance stabilized  
135 transformation data of DESeq2 and the removeBatchEffect function of edgeR  
136 (3.26.8). Differential expression between before and after treatment was performed  
137 with a correction for patient.

138 For PMNs, 1000 ng of total RNA were used for the preparation of cDNA libraries,  
139 using the TruSeq RNA Library Preparation Kit v2 (Illumina), according to the  
140 manufacturer's instructions. Library quality was evaluated using the Agilent DNA  
141 1000 Kit (Agilent) with an Agilent 2100 Bioanalyzer. Quantification was performed  
142 by amplifying a set of six pre-diluted DNA standards (KAPA Biosystems) and diluted  
143 cDNA libraries by RT-qPCR. Isomolar quantities of up to 20 cDNA libraries,  
144 barcoded with different adaptors, were multiplexed. Sequencing was performed in a  
145 single-end manner at the Greek Genome Center, using a NextSeq 500/550 75c kit  
146 (Illumina) for the in vitro samples and a NovaSeq 6000 SP 100c kit (Illumina) for the  
147 ex vivo samples, generating 75 bp and 100 bp long reads, respectively, and an average  
148 of 25 million reads per library. Raw sequence data in FastQ format were uploaded to  
149 the Galaxy web platform, and standard tools of the public server "usegalaxy.org" were  
150 used for subsequent analysis (15). Briefly, quality control of raw reads was performed  
151 with FastQC (v0.72+galaxy1), followed by removal of adapter sequences and low-  
152 quality bases using Trim Galore! (v0.6.3). Next, HISAT2 (v2.2.1+galaxy0) was  
153 applied for the alignment of trimmed reads to the Homo sapiens (human) genome  
154 assembly GRCh37 (hg19) from Genome Reference Consortium. Assessment of  
155 uniform read coverage for exclusion of 5'/3' bias and evaluation of RNA integrity at  
156 the transcript level were performed using Gene Body Coverage (v2.6.4.3) and  
157 Transcript Integrity Number (v2.6.4.1) tools, respectively. Differential gene  
158 expression was determined with DESeq2 (v2.11.40.6+galaxy1), using the count tables  
159 generated from HTSeq-count (v0.9.1) as input. The variability within and between  
160 individuals of this paired-data study was incorporated in the analysis, considering the  
161 treatment as the primary factor and the individual/patient as the secondary factor  
162 affecting gene expression.



163 Pathway and biological processes analysis was performed using the Enrichr analysis  
164 tool (14,16). Heat maps were generated using the Morpheus software (Broad  
165 Institute). Gene set enrichment (GSEA) pre-ranked analysis (1000 permutations,  
166 minimum term size of 15, maximum term size of 500) was performed using the  
167 GSEA software (Broad Institute). Gene sets were ranked by taking the  $-\log_{10}$   
168 transform of the p-value and signed as positive or negative based on the direction of  
169 fold change. Annotated gene sets from Molecular Signatures Database (MSigDB)  
170 were used as input (16).

### 171 **Cytokine measurement**

172 The levels of cytokines were measured using the LEGENDplex™ Multi-Analyte  
173 Flow Assay Kit (Biolegend) in a CyFlow Cube 8 flow cytometer (Sysmex Partec,  
174 Germany), according to manufacturer's instructions. For comparisons between the  
175 groups the Wilcoxon signed-rank test for paired samples was used. Statistical analysis  
176 was performed using GraphPad Prism (GraphPad Inc., La Jolla, CA). Significance  
177 was set at  $p < 0.05$ .

178 **RESULTS**

179 **Analysis of the molecular signature of human macrophages infected *in vitro* with**  
180 ***B. melitensis***

181 To provide a time-course analysis of the molecular alterations of human M $\phi$  during  
182 infection with *B. melitensis*, we performed *in vitro* infection of human M $\phi$ , derived  
183 from the differentiation of peripheral blood monocytes from control subjects, and  
184 compared the transcriptomic signature of untreated M $\phi$  compared to that of infected  
185 cells at 2h and 24h post-infection. Principal component analysis (PCA) revealed that  
186 there was a prominent change in the transcriptomic profile of M $\phi$  at 24h after  
187 infection compared to untreated cells and cells at 2h after infection (Figure 1A).  
188 Pathway analysis, using the Kyoto Encyclopedia of Genes and Genomes (KEGG)  
189 database, of the significantly upregulated differentially expressed genes (DEG) (False  
190 Discovery Rate/FDR <0.01) between untreated M $\phi$  and M $\phi$  at 2h post-infection  
191 revealed an overrepresentation of circadian rhythm and ribosome biogenesis  
192 pathways, whereas downregulated DEGs were enriched in pathways associated with  
193 viral infection and infection from intracellular pathogens processes, including herpes  
194 simplex virus 1 infection, hepatitis C, and salmonella infection and TNF signaling  
195 (Figure 1B, C). Interestingly, we observed a decreased expression of genes encoding  
196 proteins critical in pathogen recognition, such as *NOD1*, *TLR5*, *TLR6* and *NLRC4*  
197 (Figure 1C).

198 We next assessed the molecular changes that take place at 24h post-infection. Pathway  
199 analysis of the downregulated DEGs with the highest variance (log2 fold change > 2  
200 and < -2, FDR<0.01) showed overrepresentation of pathways associated with  
201 infection with *Staphylococcus aureus* and infection with intracellular pathogens, such  
202 as leishmaniasis and tuberculosis, as well as the pathways associated with phagosome

203 and lysosome (Figure 1D). No statistically significant pathway was observed at the  
204 respective analysis of upregulated genes. Further, analysis of the DEGs that were  
205 downregulated at 24h after infection revealed that they are involved in biological  
206 processes associated with inflammation, and more specifically with the production of  
207 IL-1 and M $\phi$  function (Figure 1E). Regarding the genes involved in the  
208 aforementioned pathways, there was a downregulation of several genes involved in  
209 the phagosome formation and function at 24h after infection, including those  
210 encoding for several Fc $\gamma$  receptors (*FCGR1A*, *FCGR2A*, *FCGR2B*, *FCGR2C*,  
211 *FCGR3A*, *FCGR3B*), toll-like receptors (*TLR2*, *TLR4*, *TLR6*), other sensors of  
212 pathogen-associated molecular patterns (*CLEC7A*, *CD14*), integrins and other  
213 receptors involved in phagocytosis (*ITGB3*, *ITGAM*, *ITGB2*, *CD36*) (Figure 3D). We  
214 also observed a downregulation in the expression of genes encoding cytokines and  
215 cytokine receptors of the IL-1 family (*IL18*, *IL1RN*, *IL36RN*), chemokines (*CCL1*,  
216 *CCL2*, *CCL7*, *CCL8*, *CCL13*, *CXCL9*) and chemokine receptors (*CCR1*, *CCR2*,  
217 *CCR3*, *CCR5*), formyl peptide receptors (*FPR1*, *FPR2*, *FPR3*), and complement  
218 anaphylatoxin receptors (*C3AR1*, *C5AR1*, *C5AR2*) (Figure 1F). Regarding the  
219 regulation of IL-1 production, we observed the downregulation of several genes  
220 encoding inflammasome sensors (*NLRC4*, *NLRP12*, *MEFV*, *AIM2*), the adaptor  
221 *PYCARD*, and the gene that encodes the effector *CASP1* (Figure 1F). Taken together,  
222 infection of M $\phi$  with *B. melitensis* drives major changes in the transcriptomic profile  
223 of infected M $\phi$ , downregulating a plethora of genes involved in the formation of  
224 phagosomes and the recognition of pathogens, in an effort to preserve pathogen  
225 survival within M $\phi$ .

226

227 **Analysis of the molecular signature of human PMNs infected *in vitro* with *B.***  
228 ***melitensis***

229 Even though M $\phi$  are the major cell population infected by *Brucella* spp, it has been  
230 previously shown that this pathogen can also infect neutrophils (17). In order to  
231 characterize the molecular signature of infected PMNs with *B. melitensis*, we  
232 performed *in vitro* infection of human PMNs for 0.5h, derived from control subjects,  
233 and compared the transcriptomic signature of untreated PMNs to that of infected cells.  
234 Pathway analysis of the significantly overexpressed DEGs (FDR<0.01), using the  
235 KEGG database, highlighted Ribosome as the top upregulated pathway in *Brucella*-  
236 infected PMNs (Figure 2A). Notably, almost all genes (75 out of the 79) encoding for  
237 structural proteins of both small and large subunits of cytoplasmic ribosomes were  
238 found significantly upregulated (Figure 2B). Respective analysis of the downregulated  
239 DEGs demonstrated modulation of several pathways, some of which were also  
240 downregulated in *Brucella*-infected M $\phi$  at 2h post-infection, such as TNF signaling  
241 and herpes simplex virus 1 infection (Figures 1B and 2C). However, various  
242 inflammation-related biological processes were significantly downregulated  
243 selectively in PMNs, namely the phosphatidylinositol signaling, NF-kappa B  
244 signaling, and cellular senescence pathways (Figure 2B, C). Amongst the  
245 downregulated transcripts in *Brucella*-infected PMNs, we identified several  
246 modulators of apoptosis (*BIRC3*, *FOXO3*, *DNM1L*, *ITPR1*, *TRAF1*, *TRAF5*) and  
247 inflammation, as exemplified by decreased mRNA expression of cytokines and  
248 corresponding receptors of the IL-1 family (*IL1A*, *IL1B*, *IL18R1*), chemokines (eg.  
249 *CCL20*), and various signaling mediators, such as kinases (*AKT3*, *ATM*, *ATR*, *CDK6*,  
250 *DGKD*, *DGKE*, *IPMK*, *IPPK*, *MAPK13*, *MAPK14*, *RPK1*) (Figure 2C).

251

## 252 **Transcriptomic profiling of active human brucellosis**

253 We further investigated the transcriptomic signature of active human brucellosis. To  
254 do so, PMNs were isolated from eight patients with active brucellosis before the  
255 initiation of antibiotic treatment (active disease) and three months after completion of  
256 the antibiotic treatment, when patients were free of symptoms (remission).  
257 Transcriptomic analysis identified 318 DEGs (FDR<0.1) (Figure 3A). DEGs that  
258 were upregulated after treatment are involved in RNA transport and autophagy  
259 pathways, whereas downregulated DEGs after treatment are involved in NOD-like  
260 receptor signaling pathway and cytokine-cytokine receptor interaction pathways, as  
261 well as several pathways associated with infectious diseases (Figure 3A). The  
262 upregulated genes that encode proteins involved in RNA transport were the members  
263 of the eukaryotic initiator factors (EIF) family *EIF1*, *EIF3I*, *EIF4A3*, *EIF5*, and the  
264 genes of the autophagy pathway were *ATG2A*, *GABARAPL1*, *TP53INP2*, *DDIT4* and  
265 *IRS2* (Figure 3B). On the other hand, we observed a downregulation of critical genes  
266 in immune regulation, such as *IL1B*, *CX3CR1*, *CCR2*, *CCR5*, *CXCR6*, *STAT1*, *AIM2*,  
267 and *CD40*, as well as genes associated with interferon signaling, such as *OAS1*, *OAS2*,  
268 *GBP1* and *GPB3* (Figure 3B). We further performed gene set enrichment analysis  
269 (GSEA) using the Hallmark Gene Set collection of the Molecular Signatures  
270 Database. We observed a positive correlation of the transcriptomic signature of PMNs  
271 during active brucellosis with IFN- $\gamma$  and IFN- $\alpha$  response and with inflammatory  
272 response (Figure 3).

273 In parallel, we performed transcriptomic analysis of PBMCs isolated from six patients  
274 with active brucellosis before and after antibiotic treatment. Transcriptomic analysis  
275 identified 62 genes with significantly altered expression (FDR<0.1) after treatment  
276 (Figure 4A). We observed that successful treatment resulted in the increased

277 expression of *HIF1A*, a critical regulator of inflammation, and of the genes that  
278 encode IL-1 receptor *IL1RI*, and its accessory protein *IL1RAP*, which form a complex  
279 that mediates IL-1 signal transduction (Figure 4A). On the other hand, there was a  
280 downregulation in the expression of genes that play a major role in immune function,  
281 such as *CD274*, which encodes PD-L1, *STAT1*, *CD3G*, the intracellular  
282 immunoglobulin receptor *TRIM21*, *CXCR6*, the lymphocytic activation molecules  
283 *SLMF6*, *SLAMF7* and genes that encode proteins important in effector cell cytolytic  
284 processes, such as *CD160*, *GZMA*, *GZMH* (Figure 4A). Moreover, several identified  
285 genes are involved in interferon-related activation pathways, such as *GPB3*, *GPB4*,  
286 *OAS1*, *OAS2*, *OASL*, *IFI16*, and *XAF1* (Figure 4A). To the same line, GSEA analysis  
287 revealed that the gene sets with the most significant positive association with active  
288 disease were IFN signaling and OXPHOS, whereas the one with the most significant  
289 negative association was the hypoxia gene set (Figure 4B). Notably, we further  
290 identified 24 genes that were differentially expressed both in PMNs and PBMCs  
291 (Figure 4C). Among these common genes, *CXCR6*, *TRIM21*, *SLAM7*, *CD274* and the  
292 genes associated with IFN signaling *OASL*, *OAS1*, *OAS2*, *GBP3*, and *STAT1* were  
293 downregulated in both datasets, whereas *IL1RI* was commonly upregulated (Figure  
294 4D).

### 295 **Cytokine levels in acute brucellosis**

296 To this point, we observed that the molecular signature that characterizes acute  
297 brucellosis is positively correlated with those of IFN- $\alpha$  and IFN- $\gamma$  response. For this  
298 reason, we measured the levels of several cytokines in the sera of patients during  
299 acute brucellosis and after successful treatment. We observed a significant  
300 downregulation in the levels of IFN- $\gamma$ , IL-1 $\beta$  and IL-6 post-treatment, whereas there  
301 was no statistically significant difference in the levels of IFN- $\alpha$ , IL-18, TNF, MCP-1

302 and IL-17A (Figure 5A-H). We further confirmed that the levels of IFN- $\gamma$  are  
303 increased in active disease in a cohort of patients with chronic relapsing brucellosis.  
304 In this cohort, the levels of IFN- $\gamma$  were increased during relapse compared to  
305 remission (Figure 5I).

306 **DISCUSSION**

307 The interaction between *Brucella* and host immune system is critical for the  
308 development of persistent infection or infection clearance (8,18). To date,  
309 transcriptomic data derived from *Brucella*-infected mouse macrophages or mouse cell  
310 lines, domestic ruminants or *Brucella*-vaccinated animals (19–25). This study  
311 analyses, for the first time, the transcriptome profile, both *in vitro*, in *Brucella*-  
312 infected primary M $\phi$  and PMNs, and *ex-vivo*, in PBMCs and PMNs derived from  
313 patients with acute brucellosis before and after treatment. This provides the molecular  
314 signature that characterizes the main host cellular immune populations during their  
315 initial interplay with invading *Brucella*, and the molecular signature of different stages  
316 of the disease.

317 Early molecular events following phagocytosis of *Brucella* by macrophages are  
318 crucial for the activation of innate immunity leading to the induction of a favorable  
319 Th1 response (8,18). Several lines of evidence indicated that *Brucella* manipulates  
320 multiple effector mechanisms in macrophages to its own benefit (9,12). In line with  
321 this, we identified that in M $\phi$  infected *in vitro* by a clinical strain of *B. melitensis*, the  
322 expression of several genes encoding key proteins involved in the recognition of  
323 *Brucella* and in the proinflammatory response against the pathogen were markedly  
324 suppressed. These alterations may initiate as soon as 2h post-infection being more  
325 prominent at 24h post infection. Interestingly, most downregulated DEGs related to  
326 phagosome, TNF $\alpha$  signaling and IL-1 $\beta$  production. Indeed, previous studies reported  
327 that various *Brucella* virulence factors and pathogen-associated molecular patterns  
328 (PAMPs), such as Type IV secretory system (T4SS), lipopolysaccharide (LPS) and  
329 outer membrane lipoproteins (OMPs) modify phagosome biogenesis and trafficking  
330 in macrophages to inhibit phagolysosome fusion, and develop suitable vacuolar



331 compartments to enable intracellular replication of the microbe (9,12). Moreover, the  
332 current study comes in agreement with previous data demonstrated that *Brucella*  
333 *Omp25* protein inhibits *in vitro* the production of TNF in human M $\phi$  and dendritic  
334 cells preventing cell maturation and antigen presentation (26–28). Furthermore,  
335 several genes encoding members of the IL-1 family (*IL18*, *IL1RN*, *IL36RN*) and  
336 inflammasome complexes (*NLRC4*, *NLRP12*, *MEFV*, *AIM2*, *PYCARD*, *CASP1*) are  
337 significantly downregulated in *Brucella*-infected M $\phi$ . Experimental studies indicated  
338 that inflammasomes and their effectors are essential for an initial effective immune  
339 response against *Brucella* infection (29–31). On the other hand, *Brucella* can regulate  
340 canonical and non-canonical inflammasome signaling and pyroptosis in macrophages  
341 by impairing caspase-1 and caspase-4/11 activation, and IL-1 $\beta$  secretion (32,33). It is  
342 intriguing that *Brucella* downregulates macrophage *MEFV* expression, the gene  
343 responsible for familial Mediterranean fever, the prototype IL-1 $\beta$ -mediated  
344 autoinflammatory disease (34). Mutations in the *MEFV* gene are highly prevalent in  
345 the Middle East and Mediterranean countries where brucellosis is endemic (35). Our  
346 data further support the hypothesis that *MEFV* mutations may provide an evolutionary  
347 selective advantage to confer protection against brucellosis (36).

348 Recently, PMNs emerge as novel players during the initial stages of innate immune  
349 response against *Brucella* infection (10). *Brucella* resists the killing mechanisms of  
350 human PMNs and induces the early death of these cells promoting their phagocytosis  
351 by M $\phi$ , which become vehicles for bacterial dispersion within the host (37). Studies in  
352 murine brucellosis proposed that infected PMNs attenuate cellular adaptive immunity,  
353 given that depletion of PMNs favored bacterial elimination (17,38). Based on these,  
354 this study examined the early transcriptome alterations of *in vitro* *Brucella*-infected  
355 neutrophils, before their premature death. *B. melitensis*-infected PMNs were

356 characterized by increased expression of genes associated with ribosome biogenesis  
357 indicating bulk induction of protein synthesis, in an effort to arm their bactericidal  
358 mechanisms and survive. Of interest and in a similar way to M $\phi$ , *in vitro* infection of  
359 PMNs with Brucella led to downregulated gene expression in key molecular pathways  
360 for PMNs physiology and function including phosphatidylinositol signaling, TNF  
361 signaling, and cellular senescence. Phosphatidylinositol signaling pathway plays an  
362 important role in membrane dynamics and trafficking, including proteins implicated  
363 in endosomal membranes and autophagosome assembly and activity (39,40).  
364 Autophagy is closely related to the intracellular lifestyle of many pathogens, including  
365 Brucella (41,42). We hypothesize that the downregulation of several autophagy  
366 sensors and regulators belonging to phosphatidylinositol pathway further modulates  
367 the autophagic capacity of PMNs against Brucella. This may also explain the inability  
368 of Brucella-infected PMNs to form neutrophil extracellular traps (NETs) (17), an  
369 effector mechanism positively associated with the autophagy machinery (43).  
370 Downregulation of the cellular senescent pathway is in agreement with the reported  
371 premature death of Brucella-infected PMNs (17). Additionally, senescence has been  
372 associated with resistance to cellular death (44). Moreover, it appears that perturbation  
373 of TNF signaling represents a common stealth strategy of Brucella to avoid both M $\phi$ -  
374 and PMNs-induced inflammation further restricting cellular immunity (11).

375 In order to investigate the impact of human brucellosis in host immunity and identify  
376 possible candidate markers of active disease and response to treatment, we next  
377 assessed the transcriptome profiling of PBMCs and PMNs isolated from newly  
378 diagnosed patients with acute brucellosis, before and three months after their  
379 successful treatment. We observed, both in PBMCs and PMNs, transcriptomic  
380 alterations related to major pathways of inflammation, supporting its role for infection

381 overcome. PBMCs from patients successfully treated were characterized by the  
382 overexpression of genes critically involved in hypoxia (*HIF1A*) and IL-1 signaling,  
383 and the downregulation of genes implicated in oxidative phosphorylation, lymphocyte  
384 activation, and cytotoxicity. In line with these data, a recent experimental study has  
385 demonstrated that absence of HIF-1 $\alpha$  renders mice susceptible to *Brucella* infection,  
386 while HIF-1 $\alpha$  reduces oxidative phosphorylation and increases glycolysis leading to  
387 inflammasome activation and IL-1 $\beta$  release in infected macrophages (45).  
388 Treatment of brucellosis upregulated in PMNs the expression of several genes related  
389 to autophagy machinery, including *DDIT4/REDD1* encoding a key regulator of  
390 autophagy-mediated NET formation (47). It seems that after clearance of infection,  
391 PMNs restored critical functions impaired by *Brucella*, such as autophagy. However,  
392 they did not acquire a proinflammatory phenotype as indicated by the downregulated  
393 expression in genes related to pathways that contain NOD-like receptor signaling and  
394 cytokine-cytokine interactions.  
395 Of note, this study identified a common set of 24 genes that were differentially  
396 expressed both in PMNs and PBMCs suggesting candidate molecular  
397 diagnostic/prognostic targets for human brucellosis. Among them, IFN pathway,  
398 which is the major driver of Th1 immunity against *Brucella* (8), appears to be induced  
399 in active disease and attenuated after treatment. Indeed, using patients' sera, we  
400 confirm at the protein level, that IFN- $\gamma$  and other Th1 cytokines, such as IL-1 $\beta$  and  
401 IL-6, were increased during active disease and significantly diminished in cured, non-  
402 relapsed patients. Collectively, these results confirmed past studies highlighting the  
403 significant role of a robust Th1 response to tackle acute infection and brucellosis-  
404 acquired cellular anergy of chronic disease (47–50).

405 In conclusion, this study provides an integrated transcriptome landscape of immune  
406 cells signature in human brucellosis suggesting candidate molecular pathways and  
407 targets for active disease and response to treatment. Based on these data, future  
408 validation and mechanistic studies may further decipher the pathogenesis of this  
409 ancient and continuously re-emerging zoonotic disease (1,2,51).

410 **Acknowledgements**

411 This study was supported by the German Federal Ministry for Education and  
412 Research (BMBF) and Greek General Secretariat for Research and Technology  
413 (GSRT), German-Greek Bilateral Research & Innovation Programme BRIDGING,  
414 grant MIS 5030062, and partially was supported by the GSRT, Research & Innovation  
415 Programme CYTONET, grant MIS 5048548.

## 416 References

1. Dean AS, Crump L, Greter H, Schelling E, Zinsstag J. Global burden of human brucellosis: a systematic review of disease frequency. *PLoS Negl Trop Dis*. 2012;6(10):e1865.
2. European Food Safety Authority and European Centre for Disease Prevention and Control (EFSA and ECDC). The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2017. *EFSA J*. 2018 Dec;16(12):e05500.
3. Franc KA, Krecek RC, Häsler BN, Arenas-Gamboa AM. Brucellosis remains a neglected disease in the developing world: a call for interdisciplinary action. *BMC Public Health*. 2018 Jan 11;18(1):125.
4. Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. *N Engl J Med*. 2005 Jun 2;352(22):2325–36.
5. Pereira CR, Cotrim de Almeida JVF, Cardoso de Oliveira IR, Faria de Oliveira L, Pereira LJ, Zangerônimo MG, et al. Occupational exposure to *Brucella* spp.: A systematic review and meta-analysis. *PLoS Negl Trop Dis*. 2020 May;14(5):e0008164.
6. Pappas G, Panagopoulou P, Christou L, Akritidis N. *Brucella* as a biological weapon. *Cell Mol Life Sci*. 2006 Oct;63(19–20):2229–36.
7. Dean AS, Crump L, Greter H, Hattendorf J, Schelling E, Zinsstag J. Clinical manifestations of human brucellosis: a systematic review and meta-analysis. *PLoS Negl Trop Dis*. 2012;6(12):e1929.
8. Skendros P, Pappas G, Boura P. Cell-mediated immunity in human brucellosis. *Microbes Infect*. 2011 Feb;13(2):134–42.
9. Jiao H, Zhou Z, Li B, Xiao Y, Li M, Zeng H, et al. The Mechanism of Facultative Intracellular Parasitism of *Brucella*. *Int J Mol Sci*. 2021 Apr 1;22(7):3673.
10. Moreno E, Barquero-Calvo E. The Role of Neutrophils in Brucellosis. *Microbiol Mol Biol Rev*. 2020 Nov 18;84(4):e00048-20.
11. Martirosyan A, Moreno E, Gorvel J-P. An evolutionary strategy for a stealthy intracellular *Brucella* pathogen. *Immunol Rev*. 2011 Mar;240(1):211–34.
12. Skendros P, Boura P. Immunity to brucellosis. *Rev Sci Tech*. 2013 Apr;32(1):137–47.
13. Kourtzelis I, Li X, Mitroulis I, Grosser D, Kajikawa T, Wang B, et al. DEL-1 promotes macrophage efferocytosis and clearance of inflammation. *Nat Immunol*. 2019 Jan;20(1):40–9.
14. Mitroulis I, Ruppova K, Wang B, Chen L-S, Grzybek M, Grinenko T, et al. Modulation of Myelopoiesis Progenitors Is an Integral Component of Trained Immunity. *Cell*. 2018 Jan 11;172(1–2):147-161.e12.

15. Afgan E, Baker D, Batut B, van den Beek M, Bouvier D, Cech M, et al. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. *Nucleic Acids Res.* 2018 Jul 2;46(W1):W537–44.
16. Lamprianidou E, Kordella C, Kazachenka A, Zoulia E, Bernard E, Filia A, et al. Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3- T cells represents a potential antitumor mechanism of azacitidine. *Blood Adv.* 2021 Jan 12;5(1):129–42.
17. Barquero-Calvo E, Martirosyan A, Ordoñez-Rueda D, Arce-Gorvel V, Alfaro-Alarcón A, Lepidi H, et al. Neutrophils exert a suppressive effect on Th1 responses to intracellular pathogen *Brucella abortus*. *PLoS Pathog.* 2013 Feb;9(2):e1003167.
18. de Figueiredo P, Ficht TA, Rice-Ficht A, Rossetti CA, Adams LG. Pathogenesis and immunobiology of brucellosis: review of *Brucella*-host interactions. *Am J Pathol.* 2015 Jun;185(6):1505–17.
19. Zhou Z, Gu G, Luo Y, Li W, Li B, Zhao Y, et al. Immunological pathways of macrophage response to *Brucella ovis* infection. *Innate Immun.* 2020 Oct;26(7):635–48.
20. Zhou D, Zhi F, Fang J, Zheng W, Li J, Zhang G, et al. RNA-Seq Analysis Reveals the Role of Omp16 in *Brucella*-Infected RAW264.7 Cells. *Front Vet Sci.* 2021;8:646839.
21. Solanki KS, Gandham RK, Thomas P, Chaudhuri P. Transcriptome analysis of *Brucella abortus* S19Δper immunized mouse spleen revealed activation of MHC-I and MHC-II pathways. *Access Microbiol.* 2020;2(1):acmi000082.
22. Hop HT, Arayan LT, Reyes AWB, Huy TXN, Min W, Lee HJ, et al. Simultaneous RNA-seq based transcriptional profiling of intracellular *Brucella abortus* and *B. abortus*-infected murine macrophages. *Microb Pathog.* 2017 Dec;113:57–67.
23. Liu Q, Han W, Sun C, Zhou L, Ma L, Lei L, et al. Deep sequencing-based expression transcriptional profiling changes during *Brucella* infection. *Microb Pathog.* 2012 Dec;52(5):267–77.
24. Rossetti CA, Galindo CL, Everts RE, Lewin HA, Garner HR, Adams LG. Comparative analysis of the early transcriptome of *Brucella abortus*-infected monocyte-derived macrophages from cattle naturally resistant or susceptible to brucellosis. *Res Vet Sci.* 2011 Aug;91(1):40–51.
25. Wang F, Hu S, Liu W, Qiao Z, Gao Y, Bu Z. Deep-sequencing analysis of the mouse transcriptome response to infection with *Brucella melitensis* strains of differing virulence. *PLoS One.* 2011;6(12):e28485.
26. Jubier-Maurin V, Boigegrain RA, Cloeckert A, Gross A, Alvarez-Martinez MT, Terraza A, et al. Major outer membrane protein Omp25 of *Brucella suis* is involved in inhibition of tumor necrosis factor alpha production during infection of human macrophages. *Infect Immun.* 2001 Aug;69(8):4823–30.

27. Caron E, Gross A, Liautard JP, Dornand J. Brucella species release a specific, protease-sensitive, inhibitor of TNF-alpha expression, active on human macrophage-like cells. *J Immunol.* 1996 Apr 15;156(8):2885–93.
28. Billard E, Dornand J, Gross A. Brucella suis prevents human dendritic cell maturation and antigen presentation through regulation of tumor necrosis factor alpha secretion. *Infect Immun.* 2007 Oct;75(10):4980–9.
29. Costa Franco MMS, Marim FM, Alves-Silva J, Cerqueira D, Rungue M, Tavares IP, et al. AIM2 senses Brucella abortus DNA in dendritic cells to induce IL-1 $\beta$  secretion, pyroptosis and resistance to bacterial infection in mice. *Microbes Infect.* 2019 Mar;21(2):85–93.
30. Lacey CA, Mitchell WJ, Dadelahi AS, Skyberg JA. Caspase-1 and Caspase-11 Mediate Pyroptosis, Inflammation, and Control of Brucella Joint Infection. *Infect Immun.* 2018 Sep;86(9):e00361-18.
31. Gomes MTR, Campos PC, Oliveira FS, Corsetti PP, Bortoluci KR, Cunha LD, et al. Critical role of ASC inflammasomes and bacterial type IV secretion system in caspase-1 activation and host innate resistance to Brucella abortus infection. *J Immunol.* 2013 Apr 1;190(7):3629–38.
32. Jakka P, Namani S, Murugan S, Rai N, Radhakrishnan G. The Brucella effector protein TcpB induces degradation of inflammatory caspases and thereby subverts non-canonical inflammasome activation in macrophages. *J Biol Chem.* 2017 Dec 15;292(50):20613–27.
33. Campos PC, Gomes MTR, Marinho FAV, Guimarães ES, de Moura Lodi Cruz MGF, Oliveira SC. Brucella abortus nitric oxide metabolite regulates inflammasome activation and IL-1 $\beta$  secretion in murine macrophages. *Eur J Immunol.* 2019 Jul;49(7):1023–37.
34. Skendros P, Papagoras C, Mitroulis I, Ritis K. Autoinflammation: Lessons from the study of familial Mediterranean fever. *J Autoimmun.* 2019 Nov;104:102305.
35. Özen S. Update on the epidemiology and disease outcome of Familial Mediterranean fever. *Best Pract Res Clin Rheumatol.* 2018 Apr;32(2):254–60.
36. Ross JJ. Goats, germs, and fever: Are the pyrin mutations responsible for familial Mediterranean fever protective against Brucellosis? *Med Hypotheses.* 2007;68(3):499–501.
37. Gutiérrez-Jiménez C, Mora-Cartín R, Altamirano-Silva P, Chacón-Díaz C, Chaves-Olarte E, Moreno E, et al. Neutrophils as Trojan Horse Vehicles for Brucella abortus Macrophage Infection. *Front Immunol.* 2019;10:1012.
38. Mora-Cartín R, Gutiérrez-Jiménez C, Alfaro-Alarcón A, Chaves-Olarte E, Chacón-Díaz C, Barquero-Calvo E, et al. Neutrophils Dampen Adaptive Immunity in Brucellosis. *Infect Immun.* 2019 Mar;87(5):e00118-19.



39. Baba T, Balla T. Emerging roles of phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate as regulators of multiple steps in autophagy. *J Biochem*. 2020 Oct 1;168(4):329–36.
40. Claude-Taupin A, Morel E. Phosphoinositides: Functions in autophagy-related stress responses. *Biochim Biophys Acta Mol Cell Biol Lipids*. 2021 Jun;1866(6):158903.
41. Starr T, Child R, Wehrly TD, Hansen B, Hwang S, López-Otin C, et al. Selective subversion of autophagy complexes facilitates completion of the *Brucella* intracellular cycle. *Cell Host Microbe*. 2012 Jan 19;11(1):33–45.
42. Skendros P, Mitroulis I. Host cell autophagy in immune response to zoonotic infections. *Clin Dev Immunol*. 2012;2012:910525.
43. Skendros P, Mitroulis I, Ritis K. Autophagy in Neutrophils: From Granulopoiesis to Neutrophil Extracellular Traps. *Front Cell Dev Biol*. 2018;6:109.
44. Sasaki M, Kumazaki T, Takano H, Nishiyama M, Mitsui Y. Senescent cells are resistant to death despite low Bcl-2 level. *Mech Ageing Dev*. 2001 Oct;122(15):1695–706.
45. Gomes MTR, Guimarães ES, Marinho FV, Macedo I, Aguiar ERGR, Barber GN, et al. STING regulates metabolic reprogramming in macrophages via HIF-1 $\alpha$  during *Brucella* infection. *PLoS Pathog*. 2021 May;17(5):e1009597.
46. Skendros P, Chrysanthopoulou A, Rousset F, Kambas K, Arampatzioglou A, Mitsios A, et al. Regulated in development and DNA damage responses 1 (REDD1) links stress with IL-1 $\beta$ -mediated familial Mediterranean fever attack through autophagy-driven neutrophil extracellular traps. *J Allergy Clin Immunol*. 2017 Nov;140(5):1378-1387.e13.
47. Giambartolomei GH, Delpino MV, Cahanovich ME, Wallach JC, Baldi PC, Velikovskiy CA, et al. Diminished production of T helper 1 cytokines correlates with T cell unresponsiveness to *Brucella* cytoplasmic proteins in chronic human brucellosis. *J Infect Dis*. 2002 Jul 15;186(2):252–9.
48. Rafiei A, Ardestani SK, Kariminia A, Keyhani A, Mohraz M, Amirkhani A. Dominant Th1 cytokine production in early onset of human brucellosis followed by switching towards Th2 along prolongation of disease. *J Infect*. 2006 Nov;53(5):315–24.
49. Skendros P, Boura P, Chrisagis D, Raptopoulou-Gigi M. Diminished percentage of CD4+ T-lymphocytes expressing interleukine-2 receptor alpha in chronic brucellosis. *J Infect*. 2007 Feb;54(2):192–7.
50. Skendros P, Sarantopoulos A, Tselios K, Boura P. Chronic brucellosis patients retain low frequency of CD4+ T-lymphocytes expressing CD25 and CD28 after *Escherichia coli* LPS stimulation of PHA-cultured PBMCs. *Clin Dev Immunol*. 2008;2008:327346.

51. Godfroid J, Cloeckert A, Liautard J-P, Kohler S, Fretin D, Walravens K, et al. From the discovery of the Malta fever's agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re-emerging zoonosis. *Vet Res.* 2005 Jun;36(3):313–26.

417 **Table 1. Characteristics of patients with acute brucellosis (AB).**

Patient#	Sex	Age (decade)	Symptoms/ Findings	Route of transmission	Wright SAT	Blood culture	Antibiotic treatment
AB1	F	4th	Fatigue, malaise myalgias, arthralgias	Consumption	1/640	N/A	Rifampicin Doxycycline
AB2	F	6th	Fever, sweating, arthralgias, peripheral arthritis	Consumption	1/320	Negative	Rifampicin Doxycycline Amikacin
AB3	M	4th	Fever, sweating, fatigue	Consumption, contact	1/320	Negative	Rifampicin Doxycycline Amikacin
AB4	M	4th	Fever, sweating, malaise, fatigue	Consumption	1/5120	Negative	Rifampicin Doxycycline Amikacin
AB5	M	6th	Fever, sweating, lumbar spondylitis	Contact	1/160	<i>Brucella</i>	Rifampicin Doxycycline Amikacin
AB6	M	7th	Fever, myalgia	Contact	1/320	<i>Brucella</i>	Rifampicin Doxycycline Amikacin
AB7	M	7th	Sweating, fatigue, low back pain	Consumption	1/320	<i>Brucella</i>	Rifampicin Doxycycline Amikacin
AB8	F	5th	Fatigue, lumbar spondylitis	Consumption	1/640	N/A	Rifampicin Doxycycline Amikacin
AB9	M	6th	Fever, sweating, malaise, fatigue myalgias, arthralgias	Consumption, contact	1/160	<i>Brucella</i>	Rifampicin Doxycycline Amikacin
AB10	M	6th	Fatigue, myalgias, arthralgias, peripheral arthritis	Contact/REV1 vaccine	1/160	Negative	Rifampicin Doxycycline
Age (years, mean±SD)		50.0±11.6					

418

419 F; female, M; male, N/A; not available, SAT; serum agglutination test, SD; standard deviation

420 Duration of antibiotic treatment was 8-12 weeks for rifampicin (600 mg/daily) and

421 doxycycline (200 mg/daily), and 2-3 weeks for Amikacin (1 gr/daily).

422 **Figure legends**

423 **Figure 1. Alterations in the transcriptomic profile of human M $\phi$  infected *in vitro***

424 **with *B. melitensis*.** (A) Principal component analysis (PCA) of the transcriptome of

425 all 12 M $\phi$  samples. T1-T4 represent untreated control M $\phi$ , T11-T14 represent samples

426 from M $\phi$  at 2h post infection and T21-T24 represent samples at the 24h time point.

427 (B) Pathway analysis of the DEGs at 2h post-infection compared to control, using the

428 KEGG database as reference. Light blue color represents statistical significance (C)

429 Heatmaps depicting the DEGs of the respective pathways. (D) Pathway analysis of

430 the DEGs with the highest variance at 24h post infection compared to control, using

431 the KEGG database as reference. (E) Enriched biological processes in which the

432 downregulated genes are involved. (F) Heatmaps depicting the DEGs of the

433 phagosome pathway, the inflammatory response and positive regulation of IL-1 $\beta$

434 production biological processes.

435 **Figure 2. Alterations in the transcriptomic profile of human PMNs infected in**

436 ***vitro* with *B. melitensis*.** (A) Pathway analysis of the DEGs from PMNs at 0.5h post

437 infection with *B. melitensis* compared to control, using the KEGG database as

438 reference. (B) Heatmap depicting the DEGs of the ribosome pathway. (C) Heatmap

439 depicting the DEGs of the pathways enriched for downregulated genes.

440 **Figure 3. Transcriptomic analysis of PMNs from patients with brucellosis before**

441 **treatment initiation and after successful completion of treatment.** (A) Pathway

442 analysis of the DEGs from PMNs after treatment compared to PMNs isolated from

443 the same patients (paired-data analysis) during active brucellosis, using the KEGG

444 database as reference. Light blue color represents statistical significance (B)

445 Heatmaps depicting the DEGs of the respective pathways. P1-P8 refers to different

446 patients. (C) GSEA for genes related to response to interferons, and inflammation.

447 **Figure 4. Transcriptomic analysis of PBMCs from patients with brucellosis**  
448 **before treatment initiation and after successful completion of treatment.** (A)  
449 Heatmap depicting the DEGs from PBMCs from patients with acute brucellosis  
450 before treatment initiation and from the same patients (paired analysis) after  
451 successful treatment. P1-P6 refers to different patients. (B) GSEA for genes related to  
452 response to interferons, oxidative phosphorylation and hypoxia. (C) Venn diagram and  
453 (D) heatmap depicting the common genes that were significantly differentially  
454 expressed in PMNs and PBMCs from patients with brucellosis after treatment.

455 **Figure 5. Levels of cytokines in the serum of patients with active brucellosis.** (A-  
456 H) Levels of IFN- $\alpha$ , IFN- $\gamma$ , IL-1 $\beta$ , IL-18, TNF, IL-6, MCP-1 and IL-17A in the serum  
457 of patients with acute brucellosis before treatment initiation and after successful  
458 treatment. (I) Levels of IFN- $\gamma$  in patients with chronic relapsing brucellosis during  
459 relapse and remission. \* $p < 0.05$ , \*\* $p < 0.01$ . Wilcoxon signed rank test.












Figure 2




# Figure 3

A

KEGG\_up after treatment



KEGG\_down after treatment




B


RNA transport




Autophagy



NOD-like receptor signaling pathway




Cytokine-cytokine receptor interaction




before  
after

C

HALLMARK\_INTERFERON\_GAMMA\_RESPONSE



HALLMARK\_INTERFERON\_ALPHA\_RESPONSE



HALLMARK\_INFLAMMATORY\_RESPONSE











Figure 4

A




before  
after

B



C



D




Figure 5

